A Harvard research team led by Kevin Kit Parker, a Harvard Stem Cell Institute principal faculty member, has identified a set of 64 crucial parameters by which to judge stem cell-derived cardiac myocytes, making it possible for scientists and pharmaceutical companies to quantitatively judge and compare the value of stem cells.
Harvard stem cell scientists studying the effect of nitric oxide on liver growth and regeneration appear to have serendipitously discovered a markedly improved treatment for liver damage caused by acetaminophen toxicity.
Harvard Stem Cell Institute researchers have identified in the most aggressive forms of cancer a gene known to regulate embryonic stem cell self-renewal, beginning a creative search for a drug that can block its activity.
Using a new, stem cell-based, drug-screening technology that could reinvent and greatly reduce the cost of developing pharmaceuticals, researchers at the Harvard Stem Cell Institute have found a compound that is more effective in protecting the neurons killed in amyotrophic lateral sclerosis than are two drugs that failed in human clinical trials.
A Harvard panel examined the problem of clinics around the world that provide stem cell treatments for intractable conditions. Although there is no medical evidence of the treatments’ effectiveness, such clinics have drawn thousands of patients from many countries.
More than 100 faculty, students, and staff from the Department of Stem Cell and Regenerative Biology turned out for a barbecue to celebrate the full-professor promotions of Kevin Eggan, Konrad Hochedlinger, and Amy Wagers.
A consortium of scientists at 20 institutions, led by a principal faculty member at the Harvard Stem Cell Institute, has used stem cells to take a major step toward developing personalized medicine to treat Parkinson’s disease.
Harvard stem cell researchers at Massachusetts General Hospital have taken a critical step toward discovering in the relatively near future a drug to control cystic fibrosis, a fatal lung disease that claims about 500 lives each year, with 1,000 new cases diagnosed annually.
Doug Melton Thomas Dudley Cabot Professor of the Natural Sciences at Harvard University and co-Director of the Harvard Stem Cell Institute
In a new study, Harvard stem cell researchers and scientists at the University of Cambridge have found that the age-related degeneration in conditions such as multiple sclerosis (MS) may be reversible.
In a study that seems to pivot on a paradox, scientists at Harvard-affiliated Dana-Farber Cancer Institute have used an immune system stimulant as an immune system suppressor to treat a common, often debilitating side effect of donor stem cell transplantation in cancer patients. The effect, in some cases, was profound.
Five years after first gaining institutional permission to attempt to produce stem cell lines via somatic cell nuclear transfer (SCNT), two Harvard researchers and a former Harvard postdoctoral fellow have closed the loop with a flurry of new studies and a commentary in several leading journals.
An innovative experimental treatment for boosting the effectiveness of blood stem-cell transplants with umbilical cord blood has a favorable safety profile in long-term animal studies, according to Harvard Stem Cell Institute scientists at Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, and Children's Hospital Boston.
Scientists at Harvard have created breathtaking three-dimensional images of an entire organ, moving a step closer to understanding the complex development of the kidney.
A group of Harvard Stem Cell Institute researchers in the Department of Stem Cell and Regenerative Biology has discovered that excitatory neurons control the positioning of inhibitory neurons in the brain in a process critically important for generating balanced circuitry and proper cortical response.
A team of Harvard Stem Cell Institute (HSCI) researchers, in collaboration with scientists at Columbia University, have demonstrated that many iPS cells (stem cells created by reprogramming adult cells) are the equal of human embryonic stem cells in creating human motor neurons, the cells destroyed in a number of neurological diseases, including Parkinson’s.
It has long been a given that adult humans — and mammals in general — lack the capacity to grow new nephrons, the kidney’s delicate blood filtering tubules, which has meant that dialysis, and ultimately kidney transplantation, is the only option for the more than 450,000 Americans who have kidney failure.
Harvard scientists at Dana-Farber Cancer Institute say they have for the first time partially reversed age-related degeneration in mice, resulting in new growth of the brain and testes, improved fertility, and the return of a lost cognitive function.
Researchers at Harvard Medical School and the Harvard School of Dental Medicine have found that by mimicking a rare genetic disorder in a dish they can rewind the internal clock of a mature cell and drive it back into an adult stem-cell stage.
An interdisciplinary group of leading Harvard geneticists and stem cell researchers has found a new genetic aspect of cell reprogramming that may ultimately help in the fine-tuning of induced pluripotent stem cells (iPS) into specific cell types.
A temporary restraining order that blocked federal funding for certain kinds of stem cell research was viewed by many as a blow to cutting-edge science. In response, President Drew Faust said, "We hope that the temporary injunction will soon be lifted and that Congress will take the steps necessary to ensure that stem cell scientists can carry on their work vigorously and responsibly, in the interests of the millions of people who may someday enjoy its benefits. ..."
The team at Children's Hospital Boston and the Harvard Stem Cell Institute were working with a new type of cell called induced pluripotent stem cells or iPS cells, which closely resemble embryonic stem cells but are made from ordinary skin cells…
Dr. Kenneth Chien speaks about a cardiac stem cell discovery that may be the first step on the path to regenerating healthy heart muscle.
When stem cell researchers in Japan and the United States announced in 2007 that they had developed long-sought methods to return fully developed adult human cells to an embryonic-like state, the world of stem cell research was turned upside down.
Biologists have long wondered why the embryonic heart begins beating so early, before the tissues actually need to be infused with blood. Two groups of Harvard Stem Cell Institute (HSCI) researchers from Children’s Hospital Boston (Children’s) and Brigham and Women’s Hospital (BWH) — presenting multiple lines of evidence from zebrafish, mice, and mouse embryonic stem cells — provide an intriguing answer: A beating heart and blood flow are necessary for development of the blood system, which relies on mechanical stresses to cue its formation.
As a girl, Elaine Fuchs borrowed her mother’s old strainers and mixing bowls to collect polliwogs, an activity she credits for her present-day career as a biologist.
Five Harvard researchers are among 50 young scientists nationwide who will have their work supported for the next six years by a new initiative from the Howard Hughes Medical Institute (HHMI).
Harvard President Drew Faust today renewed the University’s commitment to the vision of advancing interdisciplinary, collaborative science in general, and the Department of Stem Cell and Regenerative Biology (SCRB), the Harvard Stem Cell Institute (HSCI), and the Wyss Institute for Biologically Inspired Engineering (WIBIE) in particular.
Embryonic stem cell research will likely have a more sympathetic ear in the White House after November’s presidential election, but a panel of speakers said Tuesday (May 20) that an era of tight budgets may limit the practical changes researchers see.
A panel of experts said Tuesday (March 11) that stem cell research’s biggest impact on patients’ health likely won’t come from therapies that inject stem cells or implant tissues made from them, but rather from the knowledge gained by examining diseased tissues grown from the cells.
Harvard Stem Cell Institute (HSCI) and Massachusetts General Hospital (MGH) researchers have taken a major step toward eventually being able to reprogram adult cells to an embryonic stem cell-like state without the use of viruses or cancer-causing genes.
Massachusetts Gov. Deval Patrick Tuesday (May 8) announced a $1 billion biotech initiative to secure Massachusetts its position as a world leader in biotechnology and stem cell science.